Protheragen Tackles FDA Drug Shortages with GLP-1 API Expansion
19 Dec 2025 //
PHARMIWEB
Lilly`s obesity triple threat tops phase 3 efficacy forecasts
11 Dec 2025 //
PR NEWSWIRE
Ascletis Selects ASC37: First Oral Triple Agonist
30 Nov 2025 //
PR NEWSWIRE
Umbrella Labs Launches Retatrutide for Scientific Research
20 Jun 2025 //
ACCESSWIRE
Umbrella Labs Adds Retatrutide (LY3437943) to Research Portfolio
02 Jun 2025 //
ACCESSWIRE

Market Place
Sourcing Support